CagA seropositivity associated with development of gastric cancer in a Japanese population

被引:67
作者
Shimoyama, T
Fukuda, S
Tanaka, M
Mikami, T
Munakata, A
Crabtree, JE
机构
[1] St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England
[2] Hirosaki Univ, Sch Med, Dept Internal Med 1, Hirosaki, Aomori 036, Japan
[3] Hirosaki Univ, Sch Med, Dept Pathol 2, Hirosaki, Aomori 036, Japan
关键词
Helicobacter pylori; gastric cancer; CagA;
D O I
10.1136/jcp.51.3.225
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background/aims-Infection with Helicobacter pylori strains possessing the cagA gene is associated with increased risk of gastric cancer of the intestinal type. The aims of this study were to investigate whether CagA seropositivity is associated with increasing risk of gastric cancer in a Japanese population that has a much higher incidence of gastric cancer than western populations. Methods-Eighty one gastric cancer patients and 81 sex and age matched endoscopically evaluated controls were studied. Histologically, 62 cancers were of the intestinal type and 76 were early gastric cancer. Serum CagA IgG antibodies were assayed by enzyme linked immunosorbent assay (ELISA) using purified recombinant CagA protein as antigen. Polymerase chain reaction (PCR) analysis for cagA in H pylori isolates (n = 80) showed that the CagA ELISA had a sensitivity of 83.3% (controls) and 72.5% (cancers). Results-CagA seropositivity was 60% (49 of 81) in cancer patients and 44% (36 of 81) in controls. The odds ratio for the risk of cancer if CagA seropositive was 1.93 (95% confidence interval (CI) 1.01 to 3.68; p < 0.05). In the 57 H pylori positive cancer patients and their matched H pylori positive controls, the odds ratio for the risk of cancer if CagA seropositive was 2.2 (95% CI 1.04 to 4.65; p < 0.05). Conclusions-These results suggest that CagA seropositivity is associated with increased risk of gastric cancer in Japanese populations.
引用
收藏
页码:225 / 228
页数:4
相关论文
共 35 条
  • [1] Beales ILP, 1996, EUR J GASTROEN HEPAT, V8, P645
  • [2] BLASER MJ, 1995, CANCER RES, V55, P2111
  • [3] HISTOLOGICAL IDENTIFICATION OF HELICOBACTER-PYLORI IN EARLY AND ADVANCED GASTRIC-CANCER
    CARUSO, ML
    FUCCI, L
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1990, 12 (05) : 601 - 602
  • [4] cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors
    Censini, S
    Lange, C
    Xiang, ZY
    Crabtree, JE
    Ghiara, P
    Borodovsky, M
    Rappuoli, R
    Covacci, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) : 14648 - 14653
  • [5] HELICOBACTER-PYLORI AND GASTRIC ATROPHY - CANCER PARADOXES
    CORREA, P
    MILLER, MJS
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (23) : 1731 - 1732
  • [6] MOLECULAR CHARACTERIZATION OF THE 128-KDA IMMUNODOMINANT ANTIGEN OF HELICOBACTER-PYLORI-ASSOCIATED WITH CYTOTOXICITY AND DUODENAL-ULCER
    COVACCI, A
    CENSINI, S
    BUGNOLI, M
    PETRACCA, R
    BURRONI, D
    MACCHIA, G
    MASSONE, A
    PAPINI, E
    XIANG, ZY
    FIGURA, N
    RAPPUOLI, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) : 5791 - 5795
  • [7] EVALUATION OF A COMMERCIAL ELISA FOR SERODIAGNOSIS OF HELICOBACTER-PYLORI INFECTION
    CRABTREE, JE
    SHALLCROSS, TM
    HEATLEY, RV
    WYATT, JI
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1991, 44 (04) : 326 - 328
  • [8] SYSTEMIC AND MUCOSAL HUMORAL RESPONSES TO HELICOBACTER-PYLORI IN GASTRIC-CANCER
    CRABTREE, JE
    WYATT, JI
    SOBALA, GM
    MILLER, G
    TOMPKINS, DS
    PRIMROSE, JN
    MORGAN, AG
    [J]. GUT, 1993, 34 (10) : 1339 - 1343
  • [9] MUCOSAL IGA RECOGNITION OF HELICOBACTER-PYLORI 120-KDA PROTEIN, PEPTIC-ULCERATION, AND GASTRIC PATHOLOGY
    CRABTREE, JE
    TAYLOR, JD
    WYATT, JI
    HEATLEY, RV
    SHALLCROSS, TM
    TOMPKINS, DS
    RATHBONE, BJ
    [J]. LANCET, 1991, 338 (8763) : 332 - 335
  • [10] Gastric mucosal inflammatory responses to Helicobacter pylori
    Crabtree, JE
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 : 29 - 37